Patient Perspectives on Treatment Options for Older Women With Hormone Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.17129
Abstract: Key Points Question What are older women’s perspectives on recommendations for treatment de-escalation for low-risk, early-stage hormone receptor–positive breast cancer? Findings In this qualitative study of 30 participants aged 70 years or older, women expressed… read more here.
Keywords: hormone receptor; receptor positive; treatment; positive breast ... See more keywords
Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.9486
Abstract: Key Points Question Are sperm-associated antigen 5 (SPAG5) transcript or protein expressions associated with treatment response in patients with estrogen receptor–positive breast cancer? Findings In this cohort study including 12 720 patients with estrogen receptor–positive breast… read more here.
Keywords: receptor positive; positive breast; spag5; breast cancer ... See more keywords
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.5524
Abstract: Importance Multiple molecular signatures are available for managing estrogen receptor (ER)–positive breast cancer but with little direct comparative information to guide the patient’s choice. Objective To conduct a within-patient comparison of the prognostic value of… read more here.
Keywords: information; breast; positive breast; breast cancer ... See more keywords
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.1371
Abstract: Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dual ERBB2 (formerly HER2) blockade. Objective To evaluate 3-year event-free survival (EFS) and overall… read more here.
Keywords: erbb2 positive; analysis; positive breast; year ... See more keywords
Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.6036
Abstract: Importance The benefit of internal mammary node irradiation (IMNI) for treatment outcomes in node-positive breast cancer is unknown. Objective To investigate whether the inclusion of IMNI in regional nodal irradiation improves disease-free survival (DFS) in… read more here.
Keywords: irradiation; breast; positive breast; node positive ... See more keywords
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0187
Abstract: Importance Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed. Objective To determine if use of the HER2DX genomic assay (Reveal… read more here.
Keywords: assay; assay reported; breast cancer; pcr ... See more keywords
A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1516
Abstract: Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II… read more here.
Keywords: breast; receptor positive; positive breast; postmenopausal ... See more keywords
Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1600
Abstract: Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most… read more here.
Keywords: therapy; positive breast; response; breast cancer ... See more keywords
Diagnostic accuracy of de‐escalated surgical procedure in axilla for node‐positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4769
Abstract: More initial clinical node‐positive breast cancer patients achieve axillary pathological complete response (ax‐pCR) after neoadjuvant systemic therapy (NST). Restaging axillary status and performing de‐escalated surgical procedures to replace routine axillary lymph nodes dissection (ALND) is… read more here.
Keywords: cancer; node positive; cancer patients; escalated surgical ... See more keywords
miR‐142‐3p is a tumor suppressor that inhibits estrogen receptor expression in ER‐positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28263
Abstract: Estrogen receptors (ERs) are involved in the development of many types of malignant tumors, in particular, breast cancer. Among others, ERs affect cell growth, proliferation, and differentiation. The microRNA (miRNA) miR‐142‐3p has been shown to… read more here.
Keywords: breast; positive breast; mir 142; breast cancer ... See more keywords
Genetic Mutations Associated with Hormone-Positive Breast Cancer in a Small Cohort of Ethiopian Women.
Sign Up to like & getrecommendations! Published in 2021 at "Annals of biomedical engineering"
DOI: 10.1007/s10439-021-02800-4
Abstract: In Ethiopia, a breast cancer diagnosis is associated with a prognosis significantly worse than that of Europe and the US. Further, patients presenting with breast cancer in Ethiopia are far younger, on average, and patients… read more here.
Keywords: hormone positive; positive breast; african americans; breast cancer ... See more keywords